3 Cardiac Brands Specialist, Emerging Markets Generics Seller and High-Volume Ingredients Producer Stocks With a Strong Future Roadmap: JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India

Cardiac brand and ingredient pharma stocks bring together companies with a visible plan for the years ahead. JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India cover a cardiac brands specialist, an emerging markets generics seller and a high-volume ingredients producer.

This list covers three cardiac brand and ingredient pharma stocks with complete current figures: JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Cardiac Brand and Ingredient Pharma Stocks?

Cardiac brand and ingredient pharma stocks are listed drug makers that sell strong brands in India, specialty products in emerging markets and high-volume ingredients worldwide. Their earnings depend on prescriptions, launches, plant quality and export demand.

Cardiac Brand and Ingredient Pharma Stocks at a Glance

On valuation, Granules India trades at a P/E below the industry P/E, while JB Chemicals and Pharmaceuticals and Ajanta Pharma trade above it, which reflects the growth the market already expects. Readers comparing cardiac brand and ingredient pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Cardiac Brand and Ingredient Pharma Stocks Have a Strong Roadmap in India?

Cardiac brand and ingredient pharma stocks have a strong roadmap in India because wider healthcare access, strong doctor trust and global sourcing of ingredients keep lifting the revenue base.

• Doctor trust. Established brands retain loyal prescribers.
• Emerging markets. Branded exports to Asia and Africa add orders.
• Ingredient volumes. High-volume molecules support steady output.

Why JB Chemicals and Pharmaceuticals Features Among These Cardiac Brand and Ingredient Pharma Stocks

Among the cardiac brand and ingredient pharma stocks on this list, JB Chemicals and Pharmaceuticals is a Mumbai-based pharmaceutical company that sells branded formulations in India in cardiac, gastro-intestinal and other therapies, exports to several markets and runs a contract development and manufacturing business.

The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8.

Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%.

Roadmap: The company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

What to watch: Monitor the growth of key domestic brands and the order flow in contract manufacturing.

Why Ajanta Pharma Features Among These Cardiac Brand and Ingredient Pharma Stocks

Among the gastro and cardiac brand company shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.

Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%.

In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.

Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

What to watch: Monitor the pace of new launches in branded markets and the recovery trends in the United States generics business.

Why Granules India Features Among These Cardiac Brand and Ingredient Pharma Stocks

Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%.

Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

JB Chemicals and Pharmaceuticals vs Ajanta Pharma vs Granules India on Key Financials

The table below sets the three cardiac brand and ingredient pharma stocks side by side on revenue, profit and margin, using reported figures.

Ajanta Pharma posts the highest return on equity in this group at 23.3%. Ajanta Pharma has the largest FY26 revenue at Rs 5,625 crore, and JB Chemicals and Pharmaceuticals shows the fastest revenue growth with a 14.3% compound annual rate. A useful habit with cardiac brand and ingredient pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Cardiac Brand and Ingredient Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these cardiac brand and ingredient pharma stocks, the main points are: Long-term gastro and cardiac brand company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory checks. Plant inspections can affect approvals.
• Price pressure. Generic prices can fall in some markets.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cardiac brand and ingredient pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cardiac Brand and Ingredient Pharma Stocks

Cardiac brand and ingredient pharma stocks suit investors who prefer to study business strength before price moves. JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India each have a clear plan to grow. Based on the 26 October 2026 close, JB Chemicals and Pharmaceuticals trades at Rs 2,408.9, Ajanta Pharma at Rs 3,381 and Granules India at Rs 820.55. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these cardiac brand and ingredient pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track cardiac brand and ingredient pharma stocks, set price alerts and get research-backed stock ideas.

What are cardiac brand and ingredient pharma stocks?

Ans. Cardiac brand and ingredient pharma stocks are listed drug makers that sell strong brands in India, specialty products in emerging markets and high-volume ingredients worldwide. Their earnings depend on prescriptions, launches, plant quality and export demand. This list looks at three of them, JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which cardiac brand and ingredient pharma stocks are covered in this list?

Ans. This list covers JB Chemicals and Pharmaceuticals, Ajanta Pharma and Granules India. Based on the 26 October 2026 close, JB Chemicals and Pharmaceuticals traded at Rs 2,408.9, Ajanta Pharma at Rs 3,381 and Granules India at Rs 820.55. Their return on equity ranges from 11.7% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 14.3%.

Why do cardiac brand and ingredient pharma stocks have a strong future roadmap in India?

Ans. Cardiac brand and ingredient pharma stocks have a strong roadmap in India because wider healthcare access, strong doctor trust and global sourcing of ingredients keep lifting the revenue base. The main drivers are as follows. Doctor trust. Established brands retain loyal prescribers. Emerging markets. Branded exports to Asia and Africa add orders. Ingredient volumes. High-volume molecules support steady output. Together these factors give the companies on this list a visible path for growth over the coming years.

How has JB Chemicals and Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 2,463 crore in FY22 to Rs 4,208 crore in FY26, a compound annual growth rate of 14.3%. Net profit grew from Rs 386 crore in FY22 to Rs 709 crore in FY26, which works out to a compound annual growth rate of 16.4%. The company has a return on equity of 17.1%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 38,731 crore. The stock trades at a P/E of 54.6, above the industry P/E of 35.8. Looking ahead, the company is strengthening its domestic brands through field force expansion and acquisitions while building its contract manufacturing arm for global customers. A mix of chronic and acute brands supports steady prescription demand.

How has Ajanta Pharma performed financially?

Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What risks should investors check before buying cardiac brand and ingredient pharma stocks?

Ans. Investors should check a few risks before buying cardiac brand and ingredient pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices can fall in some markets. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cardiac brand and ingredient pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.